Contrast-enhanced CT shows limited dosimetric impact in MR-Linac lung SBRT planning
Contrast-enhanced CT altered mean lung electron density by approximately 12–13%, but bulk-density MR-Linac dose recalculations showed relatively small differences.
Contrast-enhanced CT altered mean lung electron density by approximately 12–13%, but bulk-density MR-Linac dose recalculations showed relatively small differences.
Across 54 oropharyngeal recurrences, accumulated dose differed from planned dose by only −0.04 Gy on average, with no systematic deficit.
Adding solid-water extensions restored PTV gamma agreement to 98–100% at 1%/1 mm, whereas unextended wide-field calibration performed poorly.
ADoTA achieved over 99% beamlet-level gamma agreement and rapid proton plan reconstruction but systematically underestimated target D98.
Retrospective DL-MAR studies achieved dose errors below 3%, but no prospective clinical validation has yet been reported.
Clinicians applying dose-equivalence models to identical scenarios agreed only 25.8%, exposing major variability in treatment gaps, hypofractionation and reirradiation.
Enhanced leaf and optimized DLG models produced similarly accurate SRS dose calculations, with DLG showing a small QA advantage.
Calibrated uncertainty thresholds kept gamma-defined dose-modelling failure below 10% while accepting 45–77% of irradiation segments.
More accurate deformable registration lowered estimated bowel dose, but produced nearly identical in-treatment adaptation decisions to simple DVH summation.
D95% and D98% PTV prescriptions produced substantial interpatient variability, while GTV- and ITV-based median or mean doses were more accurate.
Brainlab Elements commissioning was completed in one day, while Monte Carlo generally agreed with end-to-end measurements within 3%.
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
The Transformer calculated carbon-ion pencil-beam doses in 14 milliseconds with 98.0% gamma agreement at stringent 1%/1 mm criteria.
gPRIDE closely matched Monte Carlo calculations for most anatomies and completed MRI-guided proton dose calculations within 13.7 seconds.
Acuros XB was more sensitive than AAA to synthetic CT discrepancies, but target-dose differences remained small in prostate and glioma plans.